Results from 30 papers (n=1,217 patients) were included in the meta-analyses.
Overall, the proportion of combined mCRC and HCC patients with any response varied from 29% to 100% (median 82%). Any response with glass microspheres was lower than with resin microspheres, but this difference was not statistically significant at the 5% level.
mCRC: Eighteen studies (681 patients with mCRC) were included in the analysis. Based on this analysis, the specific cytostatic agents used (whether older or newer) were judged not to have affected response (p=0.96). There was a difference in any response when yttrium-90 resin microspheres were used as salvage (any response 79%) compared with first-line therapy (any response 91%); this difference was statistically significant at 10% but not at more conventional 5% level (p=0.07). Median survival duration after resin microsphere treatment ranged from 6.7 to 17.0 months and from diagnosis from 10.8 to 29.4 months.
HCC: Twelve studies (318 patients) were included in the meta-analysis. This indicated that any response proportions were statistically significantly higher (p=0.02) in resin microsphere groups (any response 89%) than glass microsphere groups (any response 78%). Median survival times (seven studies) varied between 7.1 and 21.0 months from treatment and between 9.4 and 24.0 months from diagnosis or recurrence.